Improving data sharing to increase the efficiency of antibiotic R&D

  24 October 2020

Greater investment is needed in antibiotic R&D, and more must be done to maximize the impact of such investments. More widespread data sharing, such as the recent joint data contribution from Merck and Kyorin to the Pew Charitable Trusts’ SPARK platform, has a key role.

The COVID-19 pandemic has provided a stark reminder not only of the need to be prepared before a public health crisis hits, but also of the essential role of antibiotics — in a pandemic and beyond. Unfortunately, when it comes to the growing dangers posed by antibiotic-resistant bacteria, the global level of preparedness does not match the magnitude of the threat. Indeed, recent declines in private investment in antibiotic R&D are staggering.

Author(s): Wes Kim, Kevin Krause, Zak Zimmerman & Kevin Outterson
Smart Innovations  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University


Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!